286474-59-7 Usage
Description
6-Chloro-2-fluoro-3-methylbenzaldehyde, also known as 6-chloro-2-fluoro-m-tolualdehyde, is an organic compound with a distinctive structure that features a chlorine atom at the 6th position, a fluorine atom at the 2nd position, and a methyl group at the 3rd position on a benzene ring. 6-Chloro-2-fluoro-3-methylbenzaldehyde has been studied for its toxicity in Tetrahymena pyriformis, a single-celled protozoan, through the development of a quantitative structure-activity relationship (QSAR) model.
Uses
Used in Chemical Synthesis:
6-Chloro-2-fluoro-3-methylbenzaldehyde is used as an intermediate in the synthesis of various organic compounds, particularly those with pharmaceutical or agrochemical applications. Its unique structure allows for further functionalization and modification to create a range of derivatives with specific properties and uses.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-Chloro-2-fluoro-3-methylbenzaldehyde is used as a key building block for the development of new drugs. Its distinct chemical properties make it a valuable component in the design and synthesis of novel therapeutic agents, potentially targeting a variety of medical conditions.
Used in Agrochemical Development:
6-Chloro-2-fluoro-3-methylbenzaldehyde is also utilized in the agrochemical sector for the creation of new pesticides or herbicides. Its unique structure can be exploited to develop compounds with enhanced efficacy and selectivity, contributing to more effective and environmentally friendly agricultural practices.
Used in Material Science:
In the field of material science, 6-Chloro-2-fluoro-3-methylbenzaldehyde can be employed in the development of advanced materials with specific properties, such as improved stability, reactivity, or conductivity. Its incorporation into polymers or other materials can lead to novel applications in various industries.
Used in Environmental Research:
6-Chloro-2-fluoro-3-methylbenzaldehyde's toxicity profile, as studied in Tetrahymena pyriformis, can be further explored for its potential applications in environmental research. Understanding its impact on various organisms can help in assessing its ecological risks and inform the development of safer chemicals or processes.
Used in Analytical Chemistry:
The unique structure of 6-Chloro-2-fluoro-3-methylbenzaldehyde makes it a candidate for use in analytical chemistry, potentially as a reference compound or a component in the development of new analytical methods. Its distinct chemical properties can be leveraged to improve the sensitivity, selectivity, or accuracy of various analytical techniques.
Check Digit Verification of cas no
The CAS Registry Mumber 286474-59-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,6,4,7 and 4 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 286474-59:
(8*2)+(7*8)+(6*6)+(5*4)+(4*7)+(3*4)+(2*5)+(1*9)=187
187 % 10 = 7
So 286474-59-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H6ClFO/c1-5-2-3-7(9)6(4-11)8(5)10/h2-4H,1H3
286474-59-7Relevant articles and documents
4-chloro-7-methyl-1H-indazole and chemical synthesis method thereof
-
Paragraph 0019-0021; 0024-0026; 0029-0031, (2020/01/03)
The invention relates to a chemical synthesis method of 4-chloro-7-methyl-1H-indazole. According to the chemical synthesis method, 4-chloro-7-methyl-1H-indazole is prepared from 4-chloro-2-fluorotoluene through two-step reaction including formylation reac
(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use
-
Paragraph 0859 - 0861, (2015/05/13)
The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.
